AAS in coronary disease Hermes Toros Xavier, José Eduardo Gregório Rodrigues

Abstract

Although the benefit of ASA in acute myocardial infarction (AMI) remains undisputed, a series of emerging evidence has led to uncertainty regarding the primacy of AAS throughout the lives of patients with chronic CAD. In recent clinical trials, AAS use was discontinued early as a component of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) and among patients with CAD and atrial fibrillation (AF) requiring the use of oral anticoagulants. These data may suggest that its effectiveness may also have changed in the secondary prevention of CAD, due to more modern therapies and stricter controls.